

HEPATITIS TODAY

Meeting the Challenges of a Silent Killer — Hepatitis B

CME INFORMATION

HOW TO OBTAIN CME CREDIT

- Complete this activity in its entirety
- After completing this activity, go to www.cecentral.com/getcredit
- Enter activity code MEN09222
- Log in or register for a free account
- Complete activity posttest and evaluation to obtain credit. A printable certificate will be issued

TARGET AUDIENCES

- Physicians
- Physician assistants

LEARNING OBJECTIVES

After completing this activity, participants will be better able to:

- Evaluate the latest data presented at the 2008 EASL, AASLD, and other relevant conferences and assess the impact of this new information on the management of chronic hepatitis B (CHB)
- Develop strategies for integrating updated CDC screening guidelines for HBV
- Discuss the potential impact of the National Hepatitis B Initiative for Asian Americans and Pacific Islanders on management practices in these patient groups
- Describe the main goals of CHB treatment and identify the primary end points used to measure treatment success
- Discuss novel treatment strategies for CHB; compare and contrast new approaches with current clinical paradigms
- Compare and contrast new and existing agents for the treatment of CHB
- Articulate the role of antiviral resistance in long-term management of CHB and design strategies to prevent and/or manage it

FACULTY

W. Ray Kim, MD
Associate Professor of Medicine
Mayo Clinic College of Medicine
Rochester, MN

Mark Sulkowski, MD
Associate Professor of Medicine
Medical Director, Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, MD



This activity is jointly sponsored by the University of Kentucky
College of Medicine and HealthmattersCME.

CME INFORMATION

ACCREDITATION STATEMENT

Medicine

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Kentucky College of Medicine and HealthmattersCME. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The University of Kentucky College of Medicine designates this educational activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the publication is provided solely by faculty who have been selected because of recognized expertise in their field.

STATEMENT OF DISCLOSURE

All faculty members participating in continuing medical education programs sponsored by the University of Kentucky College of Medicine are expected to disclose any real or perceived conflict of interest related to the content of the publications. Faculty disclosures are listed below.

The University of Kentucky is an Equal Opportunity University.

DISCLOSURES

W. Ray Kim, MD

Consultant: Bristol-Myers Squibb, Gilead Sciences, Roche Pharmaceuticals

Mark Sulkowski, MD

Speaker's Bureau: Gilead Sciences, Novartis

Contract Research Support: Gilead Sciences, Human Genome Sciences/Novartis, Roche Pharmaceuticals, Schering-Plough

Consultant: Bristol-Myers Squibb, Gilead Sciences, Human Genome Sciences/Novartis, Roche Pharmaceuticals, Schering-Plough

For selected readings please go to <http://www.cecentral.com/activity/dev/2035>.



This activity is jointly sponsored by the University of Kentucky College of Medicine and HealthmattersCME.



This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.

Please complete this evaluation and fax it back to 646-674-4888, attention Alexis Weinstein.

EDUCATIONAL OBJECTIVES

After participating in this activity, I am able to:

	Strongly Agree		Neutral		Strongly Disagree
Evaluate the latest data presented at the 2008 EASL, AASLD, and other relevant conferences; assess the impact of this new information on the management of CHB	5	4	3	2	1
Develop strategies for integrating updated CDC screening guidelines for HBV	5	4	3	2	1
Discuss the potential impact of the National Hepatitis B Initiative for Asian Americans and Pacific Islanders on management practices in these patient groups	5	4	3	2	1
Describe the main goals of CHB treatment and identify the primary end points used to measure treatment success	5	4	3	2	1
Discuss novel treatment strategies for CHB; compare and contrast new approaches with current clinical paradigms	5	4	3	2	1
Compare and contrast new and existing agents for the treatment of CHB	5	4	3	2	1
Articulate the role of antiviral resistance in long-term management of CHB and design strategies to prevent and/or manage it	5	4	3	2	1

ACTIVITY CONTENT

	Strongly Agree		Neutral		Strongly Disagree
This activity fulfilled my educational needs	5	4	3	2	1
The activity enhanced my ability to apply the learning objectives to my practice	5	4	3	2	1
The activity will improve my ability to effectively treat and manage my patients	5	4	3	2	1
I plan to implement the patient care/treatment strategies described	5	4	3	2	1

If changes to your practice will be implemented, please describe:

ACTIVITY EVALUATION (CONTINUED)

COMMERCIAL SUPPORT/PERCEPTION OF BIAS

	Strongly Agree		Neutral		Strongly Disagree
It was clear to me whether or not this activity received commercial support	5	4	3	2	1
The activity was free of commercial bias	5	4	3	2	1
Potential conflicts of interest by faculty were clearly communicated	5	4	3	2	1

OVERALL SATISFACTION WITH THIS ACTIVITY

	Strongly Agree		Neutral		Strongly Disagree
New and useful information presented was of high quality	5	4	3	2	1
The format of this newsletter was conducive to a positive learning experience	5	4	3	2	1
I would definitely recommend this newsletter to my colleagues	5	4	3	2	1
My overall educational experience was valuable	5	4	3	2	1

Please list any other topics that would be of interest to you for future educational activities on HBV infection:

Additional comments:

If you would like to receive educational materials in the following areas, please check the appropriate box and provide your e-mail address below:

- Hepatitis
 HIV
 Both hepatitis and HIV

E-MAIL